# Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

> **NCT02779855** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer
- Ductal Carcinoma
- Invasive Breast Carcinoma
- Invasive Ductal Breast Carcinoma

## Interventions

- **BIOLOGICAL:** Talimogene laherparepvec
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02779855
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-02
- **Primary completion:** 2020-09-20
- **Final completion:** 2025-08-26
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779855, "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02779855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*